-       Report 
- June 2023
-  48 Pages 
- United States 
   From       €671EUR$750USD£590GBP 
          -       Report 
- June 2023
-  48 Pages 
- United States 
   From       €537EUR$600USD£472GBP 
          -       Report 
- June 2023
-  48 Pages 
- United States 
   From       €537EUR$600USD£472GBP 
          -       Report 
- June 2023
-  48 Pages 
- United States 
   From       €537EUR$600USD£472GBP 
          -       Report 
- June 2023
-  48 Pages 
- United States 
   From       €537EUR$600USD£472GBP 
           -       Report 
- June 2023
-  48 Pages 
- United States 
   From       €537EUR$600USD£472GBP 
          -       Report 
- June 2023
-  48 Pages 
- United States 
   From       €537EUR$600USD£472GBP 
          -       Report 
- May 2023
-  48 Pages 
- United States 
   From       €537EUR$600USD£472GBP 
          -       Report 
- May 2023
-  48 Pages 
- United States 
   From       €537EUR$600USD£472GBP 
          -       Report 
- May 2023
-  48 Pages 
- United States 
   From       €537EUR$600USD£472GBP 
          -       Report 
- May 2023
-  48 Pages 
- United States 
   From       €537EUR$600USD£472GBP 
          -       Report 
- May 2023
-  48 Pages 
- United States 
   From       €537EUR$600USD£472GBP 
          -       Report 
- May 2023
-  48 Pages 
- United States 
   From       €537EUR$600USD£472GBP 
          -       Report 
- May 2023
-  48 Pages 
- United States 
   From       €537EUR$600USD£472GBP 
          -       Report 
- May 2023
-  48 Pages 
- United States 
   From       €537EUR$600USD£472GBP 
          -       Report 
- May 2023
-  48 Pages 
- United States 
   From       €537EUR$600USD£472GBP 
          -       Report 
- April 2021
-  191 Pages 
- Global 
        €19678EUR$22,000USD£17,309GBP 
          -       Report 
- November 2020
-  49 Pages 
- Global 
        €1179EUR$1,318USD£1,037GBP 
          -       Report 
- May 2023
-  99 Pages 
- Global 
   From       €3500EUR$4,192USD£3,186GBP 
         
      The Solid Tumor market within the context of Oncology is a highly competitive and rapidly evolving field. It is focused on the development of treatments for solid tumors, which are malignant tumors that form in the body's organs and tissues. These tumors can be caused by a variety of factors, including genetic mutations, environmental exposures, and lifestyle choices. Treatment options for solid tumors include surgery, chemotherapy, radiation therapy, and targeted therapies.
The Solid Tumor market    is driven by the increasing prevalence of cancer, advances in technology, and the development of new treatments. Companies in this market are focused on developing innovative treatments and therapies to improve patient outcomes. Examples of companies in this market include AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Merck, Novartis, Pfizer, and Roche. Show Less   Read more